Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients

Therapeutic Drug Monitoring

Volumn 18, Issue 2, 1996, Pages 200-207

  Liu, Hui Ching ^a   Chang, Wen Ho ^a   Wei, Fu Chuan ^b   Lin, Shi Kwang ^a   Lin, Shih Ku ^a   Jann, Michael W ^b  

^a TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^b MERCER UNIVERSITY   (United States)

Author keywords

Clozapine; Clozapine metabolites; Schizophrenia

Indexed keywords

CLOZAPINE; CLOZAPINE DERIVATIVE; HALOPERIDOL;

ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERSALIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; ULTRAVIOLET RADIATION;

ADULT; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; FEMALE; HALOPERIDOL; HUMANS; MALE; SCHIZOPHRENIA;

EID: 0029881519     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199604000-00015     Document Type: Article

References (33)

1. Fitton A, Heel RC. Clozapine. Drugs 1990;40:722-47.
2. Kane J, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatr 1988;45:789-96.
3. Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993;24:161-76.
4. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia. Arch Gen Psychiatr 1992;49: 345-53.
5. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-resistant schizophrenic patients. Am J Psychiatry 1991;148:231-5.
6. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55(suppl B): 133-6.
7. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993;13:383-90.
8. Centorrino FC, Baldessarni RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG. Clozapine and metabolites: concentrations in serum and clinical findings during the treatment of chronically psychotic patients. J Clin Psychopharmacol 1994;14:119-25.
9. Piscitelli SC, Frazier JA, McKenna K, et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 1994;55(suppl B):94-7.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, revised. Washington, DC: American Psychiatric Association, 1987.
11. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
12. Chang WH, Lin SK, Jann MW, et al. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. Biol Psychiatry 1989;26:239-49.
13. Chung MC, Lin SK, Chang WH, Jann MW. Determination of clozapine and desmethylclozapine in human plasma by high performance liquid chromatography with ultraviolet detection. J Chromatogr Biomed Applic 1993;613:168-73.
14. Weigmann H, Hiemke C. Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high performance liquid chromatography with ultraviolet detection. J Chromatogr Biomed Applic 1992;583:209-16.
15. Statview 512 for MacIntosh Computers, Abacus Concepts, Inc., Calabasas, CA, 1986.
16. Van Putten TV, Marder SR, Wirhing WC, Aravagirl M, Chabert N. Neuroleptic plasma levels. Schizophrenia Bull 1991;17:197-216.
17. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993;3:61-70.
18. Bertilsson L, Lou YO, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
19. Syvalahti EKG, Lindberg R, Kallo J, et al. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 1986;22:89-92.
20. Fischer V, Vogels B, Maurer G, Tynes RE. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 1992;260:1355-60.
21. Dahl ML, Llerena A, Bondesson U, Lindstrom L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphism. Br J Clin Pharmacol 1994;37:71-4.
22. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP 1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
23. Jann MW, Lam YWF, Chang WH. Rapid formation of clozapine in guinea pigs and man following clozapine N-oxide administration. Arch Int Pharmacodyn Ther 1994;328:243-50.
24. Dahl SG. Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 1982;4:33-40.
25. Chetty M, Moodley SV, Miller R. Important metabolites to measure in pharmacodynamic studies with chlorpromazine. Ther Drug Monit 1994;16:30-6.
26. Centorrino F, Baldessarni RJ, Kando J, et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994;151:123-5.
27. Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
28. Gershon SL, Meltzer HY. Mechanism of clozapine induced agranulocytosis. Drug Safety 1992;7(suppl 1):17-25.
29. Ackenheil M, Braeu H, Burhart A, Franke A, Pacha W. Antipsychotic efficacy in relation to plasma levels of clozapine. Arzneim Forsch 1976;26:1-9.
30. Task Force on the Use of Laboratory Tests in Psychiatry. Tricyclic antidepressants - blood level measurements and clinical outcome: An APA Task Force Report. Am J Psychiatry 1985;142:155-62.
31. Äsberg M, Crönholm B, Sjöqvist F, Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 1971;3:331-4.
32. Ziegler VE, Clayton PJ, Taylor JR, Co BT, Biggs JT. Nortriptyline plasma levels and therapeutic response. Clin Pharmacol Ther 1976;20:458-63.
33. Gram LF, Brosen K, Christensen P, Kraugh-Sorensen P. Pharmacokinetic considerations relevant to the pharmacodynamics of antidepressants. In: Dahl SG, Gram LF, Paul S, Potter WZ, eds. Clinical pharmacology in psychiatry. Berlin and Heidelberg: Springer-Verlag, 1987:184-92.